With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Solventum is dedicated to making healthcare more effective, intelligent, and secure. Although the company is newly formed, it builds on decades of experience tackling complex challenges across the healthcare landscape. Drawing on broad capabilities across medical-surgical products, dental solutions, and health information platforms, Solventum is helping shape the next generation of care. The company focuses on breakthroughs that combine health, materials, and data science to improve patient outcomes while giving clinicians the tools and confidence to do their best work. By working side by side with healthcare leaders and infusing each solution with both advanced technology and human insight, Solventum aims to expand access, elevate quality, and ultimately advance health for people everywhere.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Bryan Hanson

Chief Executive Officer

Heather Knight

Chief Commercial Officer

Marcela Kirberger

Chief Corporate and Legal Affairs Officer and Corporate Secretary

Rachel Ellingson

Chief Strategy & Corporate Development Officer

Wayde McMillan

Chief Financial Officer

Solventum (SOLV): Company Profile, Stock Price, News, Rankings

legacy

Solventum

solventum

Good afternoon. My name is Audra, and I will be your conference call operator today. I would like to welcome everyone to Solventum's fourth quarter 2025 earnings call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise. I would now like to turn the program over to your host for today's conference, Amy Wakeham, Senior Vice President of Investor Relations and Finance Communications. Please proceed.

Thank you. Good afternoon, welcome to Solventum's fourth quarter fiscal year 2025 earnings call. Joining me on today's call are Chief Executive Officer, Bryan Hanson, and Chief Financial Officer, Wayde McMillan. A replay of today's earnings call will be available later today on the investor relations section of our corporate website. The earnings press release and presentation are both available there now. During today's call, our discussion and any comments we make will be on a non-GAAP basis unless they are specifically called out as GAAP. The non-GAAP information discussed is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. You're encouraged to review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the GAAP reported numbers.

Additionally, our discussion on today's call will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance. These statements are made based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ from any forward-looking statements made today. Following our prepared remarks, we'll hold a Q&A session. For this portion of today's call, please limit yourself to one question and one related follow-up. If you have additional questions, you're more than welcome to rejoin the queue. I'd like to now hand the call over to Bryan.

All right. Thanks, Amy. To all of our shareholders and everyone else that's interested in the Solventum story, I just want to say thanks for joining us today as we review our fourth quarter and our full year results, along with our 2026 guidance. Well, we closed 2025 with solid momentum, making significant progress in our first full year as a standalone public company. You know, looking back at the year, I'm very proud of what we accomplished. You know, we formally launched our long-range plan and prioritized five growth drivers that are expected to now deliver more than 80% of our future growth.

We built an experienced leadership team with strong MedTech experience, but also strong transformation experience, solidified our mission and culture, revamped our innovation process, restructured our global sales organization, and through our SKU rationalization program, sale of our Purification & Filtration business, and acquisition of Acera, we rapidly advanced our portfolio strategy as well, all while managing the separation process from 3M. Inside of that, throughout the year, we consistently delivered on our strategic, operational, and financial commitments. We improved volume growth, outperformed expectations, and tripled our annual sales growth from a year ago. I think it's clear that we are moving toward our long-range revenue targets faster than expected and have programs in place to overcome external headwinds and execute against our margin targets as well.

This team's capacity to deliver results while navigating ongoing separation efforts, ERP implementations, and acquisitions and divestitures is a testament to the strong talent and culture we've already built. Building on the foundation of our sales force restructuring project, our revitalized innovation process has meaningfully increased our vitality index. As a result, we now expect a solid cadence of new product launches in our growth driver areas to drive further momentum with this more optimized sales team. As our separation progresses, we are gaining full ownership of our IT systems and freeing up needed resources to drive greater overall savings and efficiencies. Our Transform for the Future program was built to capture this opportunity, and its impact is reflected in our 2026 operating margin outlook. Okay, moving to our quarter results.

Well, the fourth quarter reflects another quarter of progress and provides a solid foundation as we head into the new year. During the quarter, we announced and closed our first tuck-in acquisition, Acera Surgical, which not only opens the door to the fast growth synthetic tissue market, it also very well complements our existing technology categories and our call points. As we move forward, portfolio optimization will remain a key lever for value creation here at Solventum. In other words, we will continue evaluating attractive assets to acquire and assessing our current assets for go forward fit. Our business performance and resulting healthy balance sheet now provide flexibility to return capital to shareholders. During the quarter, we announced a $1 billion share repurchase program, which we began executing in January of this year.

We see this as a clear and important step in achieving a more balanced capital plan. Okay, moving to our business performance in the quarter. Overall, we delivered solid sales growth with Dental Solutions and MedSurg performing better than expected. Starting with MedSurg, we continue to leverage our existing brands, our new product innovation, and newly specialized sales teams, and are seeing traction in each of our growth driver areas, which as you probably remember, are negative pressure wound therapy, IV site management, and sterilization assurance. in our advanced wound care business, we saw continued growth in negative pressure wound therapy, supported specifically by double-digit growth in Prevena and ongoing expansion of our innovative VAC Peel and Place Dressing. As mentioned earlier, we recently closed the Acera acquisition, which will now be a part of our advanced wound care business.

We're obviously very early in the integration process, but sales teams across our newly combined business will now have access to an expanded suite of technologies to offer our joint customers. With our combined clinical differentiation, our robust DME and differentiated infrastructure and proprietary technology, we have a meaningful runway for growth acceleration in this business. In the infection prevention and surgical solutions business, we saw better than expected growth, supported by our two growth driver areas, sterilization assurance and IV site management. Inside sterilization assurance, our strong brand equity continues to provide a solid foundation for our dedicated sales force, and early momentum from our three Attest sterilization product launches will continue to support the team's momentum to drive growth going forward. In IV site management, demand for Tegaderm CHG remains strong, and our global launch continues to gain momentum.

We have meaningful clinical differentiation, and our specialized sales teams are focused on converting customers from standard films to this high-value solution that reduces the risk of infection. Tegaderm CHG is still significantly under-penetrated, providing a clear runway for continued growth. In our Dental Solutions business, our core restoratives growth driver was again a key component of our performance in the quarter and was supported by our strong existing brands, recent new product launches, and the sales force specialization that we put into place in 2025. From a new product launch perspective, we continue to see strong demand for products like Clinpro Clear and Filtek Easy Match, and overall new product sales are driving the majority of our underlying business growth. Building on last quarter's service improvements, the dental team once again significantly reduced back orders, which also contributed to growth in the quarter.

Our Health Information Systems business delivered another solid quarter, supported by its growth driver, revenue cycle management. We continued to see adoption of 360 Encompass, progress against our international expansion efforts, and gains in autonomous coding. Relative to autonomous coding, our strong automation and acceptance rates are further positioning us as the largest and importantly, most capable autonomous coding vendor. Over decades, we've built deep rules and algorithms designed to ensure accurate and compliant reimbursement coding. This, combined with our vast data sets and proprietary workflows, uniquely positions us to leverage AI-driven autonomous coding our customers can trust. In summary, we finished the year building on the success and the momentum we achieved in the first three quarters. It's clear to me that we have the right team and strategy, and our momentum will continue into 2026 and beyond.

With that, I want to thank our global team for their hard work and ongoing commitment to our mission. It's you that are making a difference every single day by delivering for our patients, our customers, and our shareholders. With that, I'll turn the call over to Wayde to review our financial results and our 2026 guides. Wayde, I'll just pass it to you.

Thanks, Bryan. We reported another solid quarter as we completed our first full year as an independent public company. We made progress across both our transformation phases and turning around the business. Our commercial improvements yielded a significant increase in our organic sales growth, putting us on an accelerated path to reach our long-range plan sales growth target. During the year, we were able to absorb tariff headwinds and expand operating margins off of the Q4 2024 baseline while continuing to invest in commercial enhancements and innovation. We also moved quickly on portfolio optimization, resulting in accelerated execution of our capital plan to pay down debt. Our progress to date, combined with our planned strategies, positions us well to deliver our long-range plan margin and free cash flow targets.

I'll start with an update on our separation activities, status of portfolio moves, and then transition to our quarterly and full-year financial performance, concluding with the discussion of our 2026 full-year guidance. Overall, our work to complete the separation from 3M is going very well, thanks to the dedicated separation management teams at both 3M and at Solventum. We are progressing well on major milestones as we have now exited over 40% of our transition service agreements from 3M and remain on track to exit approximately 90% by the end of 2026. ERP deployments continue to roll out with a plan to be complete this year. We've just gone live with our latest ERP deployment earlier this month across Asia Pacific, including China, and additional countries in Europe.

We have also transitioned approximately half of the more than 1,000 systems to gain system independence from 3M, which is a significant step in our separation. Regarding supply chain, we've taken further steps to separate from 3M and have now reduced our distribution center network to 55 locations. Progressing towards our goal of 45. The P&F divestiture activity continues to progress as planned with a target completion at the end of 2027. There is close collaboration to ensure business continuity from Solventum to support the buyer's integration efforts across the nearly 200 transition service agreements. Shifting to our recent Acera acquisition, our early integration efforts are off to a good start following the close at the end of December. Our main focus is sustaining and accelerating the momentum that the team has generated in recent years. Turning to our Q4 results.

Starting with top-line performance, sales of $2 billion increased 3.5% on an organic basis compared to prior year and declined 3.7% on a reported basis, which reflects the first full quarter impact of the P&F divestiture following the sale in September 2025. Foreign exchange was a 170 basis point benefit to reported growth, while the net impact of the P&F divestiture and Acera acquisition represented an 890 basis point net impact on our reported growth. Overall, we had stronger than expected sales growth driven by MedSurg and Dental. Volume remains the main driver of growth, and pricing remains within the expected range of ±1%. Our SKU rationalization program also remains on track with 70 basis point impact in the quarter, bringing the full year impact to 60 basis points. Moving to the segments.

MedSurg delivered $1.2 billion in sales, an increase of 3.2% on an organic basis. Within MedSurg, the advanced wound care business grew 1.7%. Solid performance in our negative pressure wound therapy growth driver was partially offset by headwinds in the separate advanced wound dressings category, which was impacted by SKU exits and back orders. Infection prevention and surgical solutions continues to outpace our expectations, delivering 4.2% growth that was driven by strong business performance, partially offset by the remaining reversal of first half volume timing and the SKU rationalization program. Our Dental Solutions segment delivered higher than expected $343 million in sales, an increase of 5.9% on an organic basis. Growth was driven by core restoratives, which benefited from further back order improvement.

During 2025, the supply chain team led multiple efforts that helped reduce back orders to historic lows. On a normalized basis, Dental grew closer to 3%. Our HIS segment also contributed to our performance with $348 million in sales, an increase of 3.2% on an organic basis, driven by revenue cycle management software solutions and performance management solutions. This growth more than offset expected declines in clinician productivity solutions. Looking down the P&L, gross margins were 53.5% of sales, a 230 basis point sequential reduction, which reflects higher logistics costs and timing of manufacturing performance. Higher logistics costs were mainly driven by ERP and distribution center cutover mitigation efforts in the quarter. These headwinds were partially offset by the benefit of the P&F divestiture. On a normalized basis, gross margins were closer to 55%.

Sequentially, operating expenses reduced to $672 million from $739 million, which reflects the P&F divestiture, timing of project spend, and cost management. In total, we delivered adjusted operating income of $397 million or an operating margin of 19.9%, below expectations due to gross margin headwinds, partially offset with lower operating expenses. Moving down the P&L to non-operating items. Our net interest expense and other non-operating spend improved versus Q3, driven by a $30 million reduction in interest expense and higher interest income. These improvements are due to the full quarter benefit of the P&F divestiture, which resulted in a $2.7 billion debt paydown and a higher cash balance.

Our effective tax rate of 16.6% was favorable due to an end-of-year release of tax reserves and a regional tax provision in combination with favorable geographic mix. We delivered earnings per share of $1.57, driven by sales outperformance as headwinds and gross margin were partially offset with operating expense savings. Shifting to our balance sheet, we ended the quarter with just under $900 million in cash and equivalents and net debt of $4.2 billion. This includes funding the $725 million Acera acquisition, which closed on December 23rd. We're in a healthy position to accelerate our capital allocation strategy as indicated by our recent $1 billion share repurchase authorization and maintain flexibility to pursue tuck-in M&A.

We generated cash flow of $33 million, below our expectations due to higher divestiture costs, the earlier than expected close of the Acera acquisition, as well as higher costs to support the ERP and distribution center cutovers. Moving to full year 2025. We delivered 3.3% organic sales growth ahead of our expectations of 2%-3%. When normalizing for SKU exit impact and mainly the benefit of backorder improvement in Dental, our growth was approximately 3.5%. Operating margins finished at 20.5% within our assumptions of 20%-21%, while absorbing 65 basis points of tariff impacts that were not contemplated at the beginning of the year. We also completed the Solventum Way restructuring program, exceeding expectations and delivering annualized savings of approximately $125 million at a lower total cost of $90 million.

Our adjusted tax rate of 19.1% was also better than our assumption of 20%-21%. At the bottom line, we generated non-GAAP earnings per share of $6.11, also ahead of our expectations of $5.98-$6.08. Free cash flow was -$10 million, below our expectations of $150 million-$250 million due to higher Q4 costs to support portfolio moves and ERP cutovers. Excluding these, we were in line with our expectations. When adjusting for the P&F divestiture and separation costs during 2025, free cash flow would have been approximately $1 billion for the year. Now, turning to our 2026 guidance. Starting with our top line, we are guiding to an organic sales growth range of 2%-3%.

This translates to 3%-4%, excluding the continued estimate of 100 basis point impact of SKU exits for 2026. While not reflected in our organic sales growth outlook for 2026, we expect our recent Acera acquisition to contribute meaningfully to our reported growth going forward and will roll up as part of advanced wound care sales. We also expect a modest 100 basis point tailwind for foreign exchange, mostly in the first half. Looking down the P&L, we estimate operating margins of 21%-21.5% for the year, expanding from the 20.5% full year 2025. Underlying the 50 basis points to 100 basis points of margin expansion is a combination of sales leverage, programmatic savings for supply chain, and our Transform for the Future program.

We expect portfolio optimization for divestiture and acquisition activity to be neutral to operating margins. Regarding tariffs in place before last week's Supreme Court ruling, we estimate full year impact of $100 million-$120 million. Given the evolving nature of the environment, at this time, we are assuming the impact under any new tariffs will be within a similar range. For earnings per share, we are guiding to a range of $6.40-$6.60. For free cash flow, we are expecting approximately $200 million in 2026. Excluding mainly the impact of costs to separate from 3M, as well as payments due to 3M and costs to support the recent divestiture, we would expect to be closer to $1 billion. As a reminder, separation costs reduce significantly in 2027 as we complete the separation from 3M.

Other considerations for 2026 include capital expenditures of $400 million-$450 million, an effective tax rate between 19.5%-20.5%, and non-operating expenses of $300 million, primarily due to net interest expense of around $270 million. To provide some additional color related to our Q1 2026, remember we had a tough comparison given the approximately 180 basis points of additional sales volume benefit in the prior year. On gross margins, Q1 will reflect the typical sequential seasonal pressure, while year-over-year will reflect the additional tariff impact headwinds. All in, we anticipate operating margins will again be the lowest of the year. In conclusion, we delivered another strong quarter to complete our first full year post-separation.

We're making great progress on our separation from 3M and on our portfolio moves to divest P&F and integrate Acera. We're moving with urgency towards our long-range plan goals of accelerating sales growth to 4%-5%, operating margins of 23%-25%, growing earnings per share at a 10% CAGR, and free cash flow conversion rate above 80%. We wanna extend our gratitude to all Solventum team members for their hard work and commitment to our values and mission, enabling better, smarter, safer healthcare to improve lives while consistently delivering or exceeding on our financial goals. With that, we'll hand it back to the operator for the Q&A portion of the call.

Thank you. We will now begin the question and answer session. If you would like to ask a question, press star then the number one on your telephone keypad. If you would like to remove yourself from the queue, press star one again. As a reminder, please limit yourself to one question and one follow-up. We'll take our first question from Travis Steed at Bank of America.

Hey, thanks for taking the question. I guess first on margins. Wayde, I don't know if there's anything one time in Q4. It was a little light versus the street in the quarter. Then on 2026, if you can maybe elaborate a bit more on kinda what's assumed in that 50 basis points to 100 basis points. How much of the $500 million cost savings is baked in into that and anything else that you'd kinda frame up for the margins in 2026?

Sure. Hey, Travis. Margin's obviously an important part of our story. As we think about Q4 first, approximately 150 basis points of the cost in our gross margins was one time in nature. You'll see in our prepared remarks that we shared a more normalized gross margin of 55% is more what we would have expected. We saw a lot of separation activity in Q4, so it ended up just costing us more. If we think about operating margins, certainly lower than we expected, but really just driven by that headwind in gross margins. We were able to offset it partially with some savings in our operating expenses. Then as we think about 2026.

First of all, just say we are committed to growing our sales as well as expanding operating margins each year. In, in that theme, we're now planning to expand operating margins 50 basis points to 100 basis points in 2026, as you mentioned. A couple things that are important here. Certainly, tariffs are a headwind for us again in 2026. People may recall that we have a very fast inventory turn, and so we had approximately two quarters of impact of tariffs in 2025, and so we'll annualize that in 2026. You'll see from our prepared remarks, it's about a doubling of the tariff headwinds for us. With that in mind, it's a pretty significant margin expansion.

The drivers of that are sales leverage as we continue to drive sales on an accelerated basis, as well as our programs within gross margin. We've talked about programmatic savings. We gave a lot of detail at our Investor Day, we've got significant effort to drive favorable gross margins over time. As you mentioned, Travis, our more recently announced Transform for the Future restructuring project, which is a longer range project that is targeting several areas of efficiency, and we will start to see some of that in 2026, but it'll benefit us more over the long term. You put all that together, we do think we've got a nice operating margin expansion story again in 2026, despite the tariff estimate that we have in the numbers at this time.

Okay. Thank you. I guess, my follow-up question, since there's been more focus on the healthcare IT business and some of the AI stuff that's going on, just would kinda love to give you the opportunity to kinda maybe explain that and explain your business a bit more for investors.

Yeah. Thanks, Travis. I'll probably answer that one. I assume, seeing your note, that you might ask that question too. We're actually betting which question you would ask first, and you asked both questions.

I know you pretty well. I would just say first of all, I think it's important to state right out of the gate, we actually see AI as an opportunity more than we do a threat. I think that's. You could probably end the statement there, but I think that's a really important statement to make. Then there's probably three vectors to look at it, which I think could be helpful to people. Number one, I think we see artificial intelligence as a lever to drive autonomous coding. That's why we've been spending so much in that area, and that's what's, you know, driving us in autonomous coding. We don't see it by itself as the answer to autonomous coding. I think that's important. By itself, it is not the answer. It's just a piece of the equation.

We really don't see AI, again, by itself as a competitor. We see it as a tool. We see it as a tool, a variable in the equation to solve for autonomous coding. Remember, autonomous reimbursement coding, not computer coding, right? Then three, and this is important because AI will be available to anybody who wants to use it in autonomous coding or revenue cycle management. We truly do believe that we're differentially capable of using AI because, number one, we've been in the market for decades, and as a result of that, we have vast number of proprietary, I'm gonna call algorithms and rules that we have around reimbursement coding. Actually close to a million plus of those rules and algorithms, which is substantial.

Of course, because we've been working at scale with hospitals, we have, you know, very vast data sets as well. We really believe that what we have available to us allows us to train AI in ways that others can't. We actually look at this as an opportunity more than we do a threat. I appreciate you asking the question because there's a lot of folks that may not see it that way.

We'll move next to Jason Bednar at Piper Sandler.

Hey, good afternoon, everyone. Thanks for taking the questions. Wayde, I wanted to come back to some of the guidance points you were making. I appreciate all the color around the first quarter. Maybe wanted to give you an opportunity to talk if there's any other sequential call-outs. Last year, 2025 was lumpy. It was good lumpy, but lumpy in that you had the ERP cutovers, the DC cutovers that, you know, just created some volatility in the volume. Anything else you'd call out as we try to model throughout the year? You know, within that also in the first quarter, should we be considering any headwinds tied to just some of the weather dynamics that, you know, may or may not have impacted volumes for your businesses in the first quarter here?

Got it. Hi, Jason. I can certainly start that one for you. I'm glad you picked up on the Q1 comments that we had in our prepared remarks because it is the one quarter for us that's a little more challenging, that the other quarters in the year look more stable. Maybe I'll just summarize the information that we shared, and it's really in the three areas: sales, gross margin, and OpEx. For sales, we had the 180 basis points of tough comp, and that's put a lot of pressure on our Q1 sales here. If you just take the full year guide of 2%-3% and you take the midpoint, 2.5%, if you use the 180 basis points of headwind, you'll get just under 1%.

That's how we'd like people to think about the first quarter, and I think that'd be a reasonable place to start. If you move down the P&L, operating margin is setting up to be the lowest of the year in Q1. You know, sequentially down from Q4 2025 to Q1 2026. That's similar to what we experienced last year in 2025. Very similar setup to last year. That's really driven by gross margins, which, relative to the normalized 55% we gave for Q4, we would expect to see some normal sequential seasonal headwind to that moving from Q4 2025 to Q1 2026. Same setup again as last year. You know, keep in mind, tariffs are a headwind in the first half as well before we annualize them.

When you move down to operating expenses, kinda similar here. We'll have higher OpEx in Q1 as we have some seasonally higher expenses than Q4 2025. Q4 2025 was a little unnaturally low as we had some favorable project timing. Just given the gross margin pressures we were having in the quarter, we did some cost reduction initiatives that gave some favorable OpEx in Q4 as well. We don't have any weather specific things to that specific question, Jason. Nothing that we would call out. Again, I would just say for the remainder of the year, the setup looks more consistent.

Other than I would just highlight, and it was really the driver of that volume in Q1, this first half, second half impact of IPSS. We had a lot of volume, mainly in the first half last year. These were mostly ERP timing-driven impacts. The good news is they're all contained within the year. First half, second half dynamic, mostly a Q1 additional volume, Q3 give back. The good news, the story actually gets quite simple at a full year basis, but there is that trade-off, particularly in IPSS, between mainly Q1 and Q3.

All right. Super helpful. Thank you for that. Bryan, I wanted to shift over to you. Bigger picture question. You mentioned product pipeline that's expanded, you know, within some of the core growth categories you've identified or you identified at your investor day. Can you give us a sense as to some of the things you're more excited about or expected to be more impactful when we look out this year and also next year, really to help bridge to that 4%-5% growth target, knowing that you're, you know, targeting 3%-4% underlying growth this year? What helps accelerate you that last 100 basis points to get to those LRP targets you have out there?

Yeah. Yeah. Appreciate the question. I would say, you know, maybe first just taking a step back because I have a feeling some of our solvers are listening to this call as well. I just wanna say that I appreciate the work that they put into revamping and revitalizing our innovation process, and it's paid dividends. You know, as we talked about in prepared remarks, vitality index has gone up, the cadence is more focused to products that we're gonna see. I'm not gonna speak specifically about any individual product because, you know, competitive reasons, but maybe I'll give you some color that I think could at least help. We've got close to 20 new products that we're gonna be launching now over the next two years, relatively evenly over those two years. It's not back-end loaded.

Those, as you would expect, just given the size of MedSurg, almost half of those are gonna be in MedSurg. The other half is split between HIS and Dental. As you would expect, a decent portion of those are gonna be inside of the growth driver areas. It's not just those. I kinda look at it as a three-legged stool, right? You've got this opportunity for new products, in that revitalization of innovation that I've been talking about. We also have existing products and brands that are really strong in the marketplace. I think some people underappreciate the fact that they're also under-penetrated. With the new specialized sales organization, we can get after that under-penetration, even with existing brands.

The third leg of the stool is just the, you know, the commercial enhancements we've made. Those really have three components to it. First is specialization, which is probably the most important. We're also training those individuals now to be more clinically adept, which is very important when you have clinically differentiated technology. The final one is just to make sure that we have a sales operations team that is best in class to focus the organization and to make sure that they have the tools to be successful in the field. It's all three of those, really, that's driving the growth.

Thanks for the question. This is Dylan Finley on for Kevin. Maybe for a minute, could you guys talk about the strong outperformance in dental this quarter? Again, you grew organically nearly 6%. How much of that was volume expansion versus price capture related to or not related to tariffs? What do you think a normalized growth rate looks like in dental, you know, controlling for any sellouts or unusual comps?

Okay. Yes. Again, that was another one we thought we'd probably get a question on because it was pretty standout quarter again for Dental. Again, because I know they're listening to the call, congratulations, great quarter. I would say well, I know the biggest underlying reason for growth is new products. They have done a nice job of revitalizing innovation, launching new products, and that's really what's driving our underlying business performance. Now in the quarter, I think we said in the prepared remarks that another factor was back order recovery. That's the second quarter in a row. They've done a really good job of capturing back order recovery, that's boosting us. That's more of a one-time thing. I wouldn't think about that as a go-forward opportunity, it definitely helped us in the quarter.

When we think about the market, 'cause I know that's probably inside of your question as well, 'cause I'm sure you're covering other companies in dental, we kinda look at it the same as what you're hearing from others. It's a stable to maybe slightly improving market. That's really the way we look at it. Stable market, slightly improving. We would expect that to go forward in 2026. Really the momentum here is the new product development. They're just doing a great job with that specialized sales organization driving it right now.

Did you have another one? I didn't wanna cut you off there. Sorry about that.

Oh, sorry. Yeah. If I had a moment. Looking at the $500 million, the Transform for the Future program. Apologies if this was hit on earlier, but, you know, what should we contemplate regarding the phasing of those, both the costs going into the restructuring and the timing of the benefits? You know, is that really a big growth driver, discreetly as we look at the benefit for 2026, or is the phasing more, you know, 2027 and thereafter?

Bryan Hanson can start that one if you want. Obviously very important program for us. It is a multi-year program, from starting this year, 2026 into 2029 and 2030. Just to highlight, you know, as you said, it's a $500 million cost takeout program. It's meant to support both margin expansion as well as opportunities to meaningfully invest for growth. We wanna make sure that we're driving efficiencies that, despite things like tariffs, we've got enough efficiencies going so we can continue to reinvest for growth given the importance of us continuing to drive and accelerate that sales growth line. Just a little bit more about the program itself. It's targeted at transforming our cost structure. I mentioned the operational efficiencies and then repositioning us for that profitable growth.

We'll be looking at streamlining systems, increasing automation. It's a really comprehensive program. To your question on the phasing, we haven't given details on that. We're still developing the program. As I said, it's a multi-year program. I would say just generally, we will start to benefit from the program in 2026, but the majority of the benefits will be in 2027 and beyond, as it just takes time to put the programs together and then execute on them.

One other thing maybe that to add to that too, what's very important about this program. It is a cultural shift for our organization all around the concept of continuous improvement. We've got this mantra here that we can be satisfied. We can be happy, but we can never be satisfied, right? We can be happy and celebrate success, but we can always get better. That's what this program is. It really is the concept of transforming for the future through continuous improvement. It's not just at the senior level of the organization. This is transcends the organization. We're asking everybody to get involved in the program. It really is a cultural event, not just a savings program.

We'll take our next question from Ryan Zimmerman at BTIG.

Good afternoon. Thanks for taking our question. You know, just following up on the HIS comments and, you know, there's been a lot of investor focus on this late. I appreciate your answers earlier, Bryan. I gotta dig a little deeper, though, and just kinda ask, you know, is there any guardrails that, you know, you wanna put around this? You know, if this is up for competitive, you know, bidding or competitive entrants and so forth, I mean, how should we think about maybe what's contractually obligated, you know, over a certain time period or any other additional details I think you can give that, you know, again, kind of, you know, isolates what impact there may or may not be around the HIS business?

Yeah. I would tell you two things here. Number one, we have pretty long contracts, multiple year contracts, and so we feel comfortable. I don't wanna rest on that because I do believe we have significant differentiation here. We're a leader today. We absolutely expect to be a leader in this transformation in the future. There's no question in our minds. We, we do have contractual obligations in our favor, and there's switching costs associated with this. It doesn't happen overnight. And I think very importantly for people to remember here is you make mistakes, even small ones in your reimbursement model and in your coding. Not only do you lose revenue, you have the risk of compliance concerns, and there's a trust factor that goes into that.

As a matter of fact, we look at autonomous coding competitors as risking autonomous coding because we don't think they're gonna do it the way we would do it, right? Well, again, using all those rules and all those algorithms that we have that are proprietary to us. We truly do believe we're going to win, we're gonna transform. We're already leading. We feel like we're gonna continue to lead. We do believe, we really do believe that that's just the way it's gonna be. I don't see this at this point in time as a risk. I see it as an opportunity, and the contractual piece helps, but we're not gonna rest on that.

Yeah, no, that's helpful. I appreciate the color there. You know, maybe turning to Acera. What are you embedding for expectations on Acera if you can provide any, you know, high level commentary around it? I mean, you know, I think it was doing, call it $90 million at the time of acquisition. You know, where can that sustain once it turns organic, and, you know, from a contribution to growth standpoint?

Well, I'll tell you, we wouldn't have bought the asset if we didn't believe that it had a real opportunity to help advanced wound care and MedSurg and the total business from a revenue growth standpoint. We feel like it's a great starting point, but it is just a starting point. To give you some perspective on it, they're in a $1 billion market growing 10% right now, and they're in a subcategory synthetics inside of that market that's more attractive, and they've got differentiation in that space. It is a healthy double-digit grower for us.

I want to continue to remind people, it's in the space we already play and have commercial infrastructure. We have a force multiplier effect, given our two organizations coming together from a commercial standpoint, also eventually from an innovation perspective. I feel really good about this as a separate growth avenue for advanced wound care for the total business. It's profitable. It's really nice profitability.

We'll move next to David Roman at Goldman Sachs.

Thank you. Good afternoon, everyone. Maybe I could just go into the Dental dynamic in a little bit more detail here. I think last quarter there were some more set of dynamics at play here. Maybe Bryan, if you kind of maybe template Dental as one of the businesses where you have I think you said on the follow-up last quarter that it is a good example of when you have new products, what can happen to the top line, but you're seeing kind of that impact in one of those slower growing categories that you serve. Maybe you could just extrapolate the experience in dental to when you think it's reasonable to expect that same dynamic to play through in MedSurg and HIS, and just sort of follow up on the buyback.

Yeah. David, thanks for the question. I agree. I think dental laid out the roadmap that was pretty clear to people, but you're already seeing it in MedSurg. It's not just the commercial enhancements that we've made. We are launching new products in both MedSurg and HIS. Just to recap, I'll give you some of them, not a full list of them, but backfill in place was a big one. Tegaderm CHG was launched in the U.S., but now it's on a global launch, so we're rolling that out around the world. We've had CHG and Ioban as well, which is a new product that we use in surgical procedures. We've had three Attest sterilization products. The eBowie-Dick was also launched. We've had a number of products launched in MedSurg.

In HIS, you've seen various applications in autonomous coding and a lot of applications from Encompass 360 when we look at outside the U.S. implementation. They're not having product launches right now. The key thing that's driving those product launches is the commercial enhancements. We didn't have those before, and as a result, those products are being launched into a void, if you will, a general sales organization. So we're already beginning to see the momentum from those new products. As I said before, we've got almost 20 new products coming over the next two years.

Got it. Then, maybe Wayde, it looks like the share count still stepped up on both a year-over-year and sequential basis. You obviously announced a large buyback authorization in November. How are you thinking about deploying the buyback? You know, I think that there was quite a bit of volatility in the stock over the past several months. Maybe what's sort of the strategy behind the buyback and what are the factors that would drive you to deploy it either on a programmatic or more significant basis?

Sure. Yeah. Hey, David. I think directionally it's reasonable to think about the authorization as offsetting the impact of our stock-based comp dilution and holding that share count relatively flat. I think that's one of the objectives that we have. As you said, without a share repurchase in place over the previous year, our share count went up. One of the major goals here is to number one, offset that stock-based comp. Over time, you know, it is an opportunity for us. We've got room within the authorization if we see a need or a reason, depending on performance of the share price, to potentially purchase more shares. Obviously, if we do something like that, we have to work it through with our board and make those decisions as well.

I think just taking a step back, we're very happy with the accelerated capital plan over the last year, with our ability to pay down debt. You know, if you remember back from our investor day, that was the primary objective. Most spins spin with a pretty significant amount of debt, and one of our primary goals was to pay down that debt. We did that in accelerated fashion, and now we're in a position to have more balanced return and returning capital to shareholders via this authorization. As Bryan said in his prepared remarks, we started that in January. This is our first quarter, and we're pretty excited to be moving in this direction as well.

Our next question comes from Brett Fishbin at KeyBanc Capital Markets.

Hey, guys. Thank you very much for taking the questions. First, just wanted to ask on the overall organic revenue guidance of, you know, 2%-3%, and was curious if you could just, you know, directionally provide any commentary on how you're thinking about that across the different segments, whether we should expect any, you know, material departure from what we've seen on a normalized basis in 2025. Also if the 100 basis point impact from SKUs would be more pronounced in any specific quarter.

You know, maybe, to rephrase that question on any specific quarter, you could maybe answer that, but also any specific business.

Yeah. Yeah, that's the key. Yeah, maybe we'll start there. We don't see a significant difference across the quarters from the program at this time. Nothing to share there. As Bryan just highlighted, we do see a significant more impact within MedSurg and particularly the IPSS business. As we move from 60 basis points of impact in 2025 to 100 basis points of impact in 2026, we'll see the majority of that 100 basis points hitting in the IPSS and MedSurg business. Then back to the front end of your discussion, and, you know, Bryan can start that one.

You know, we obviously put a lot of thought into this guidance. Glad you brought it up because it gives us an opportunity to talk a little bit about it. We did intentionally share that for 2025, our sales growth rate on a normalized basis was about 3.5%. That's important stake in the ground for us. It's really normalized for both the SKU program as well as mainly the dental backorder. With that 3.5% in mind, the way we looked about our guide for 2026 is we put that at the midpoint of our ex-SKU guide. You know, we're 2%-3% guide for 2026 on a 100 basis point SKUs, we're guiding 3%-4%.

What that really means is if we continue to perform at an accelerated rate here in 2026, we had big step up in our growth in 2025, and if we continue that momentum, continue to perform at that level, be at the midpoint of our guidance for 2026. Of course, at the high end, more of 4% on an ex-SKU basis, will be above last year's strong performance. We're very focused on getting to that because then that would put us on an accelerated basis getting to the low end of our 4%-5% target for our long range plan. On an ex-SKU basis, the high end of our guidance is already touching the low end of our long range plan guidance for 2028.

We do feel that 2025 was a very strong year where we really accelerated the sales growth rate. We shared some of that detail in our prepared remarks, so I won't repeat it here. That's some color in behind the full year. You did call out segments as well. As you know, we don't guide at the segment level, but we can provide a little bit of color here. Overall, we expect all segments to improve their underlying growth year-over-year. Again, the momentum that we see in the business, if it continues, will be at the high end.

'Cause it would be, MedSurg is gonna be impacted more by SKU, and obviously Dental is gonna be impacted by the backorder recovery, comp. Outside of that, no major impacts to the businesses.

All right. That was super helpful. Just for my follow-up question, wanted to ask, you know, during the fourth quarter, you announced some changes to the management structure and was hoping you could just touch on, you know, your decision to implement a Chief Commercial Officer position and any thoughts on how that impacts the broader strategy for Solventum. Thank you.

It's funny because that feels like old news to me already. I was looking around going, "What's he talking about?" Yeah. As you know, we brought Heather in to be the primary leader of our businesses. She's the Chief Commercial Officer now. And I feel very fortunate to be able to bring Heather in. She and I have a history. We worked at Covidien together. She's worked with me in the past. She's a very strong operator. It was just serendipity that she became available at the same time that Chris was gonna be exiting the organization. Very lucky to get her. It was really just the continuation of the strategy, which would have been to combine the businesses under a leader.

Chris, for his own reasons, couldn't do that. Heather was available, and we were able to get her, which is fantastic for us. I wouldn't read anything else into it other than the fact that we've got a great operator now looking at synergies across our businesses.

Our next question comes from Vik Chopra at Wells Fargo.

Hi, it's Leah calling in for Vik. Thanks for taking the question. My first one's on ERP. I think you have another ERP implementation coming this year. Last year when you had the European one, there was some pull-forward buying in the first half. Is that something we should consider for 2025? I have a follow-up.

Solventum (SOLV) Q4 2025 Earnings Call Transcript

Company Participants